t
Hemogenyx Pharmaceuticals plc announced that all five resolutions proposed at its Extraordinary General Meeting (EGM) held on 09 December 2024 were duly passed. The resolutions included granting Directors authority for share subdivision, reclassification, consolidation, allotment of shares, adoption of new articles, and disapplying statutory pre-emption rights. 'Votes for' these resolutions ranged from 92.24% to 95.41% of votes cast, representing between 37.98% and 38.79% of the Company's issued share capital as of 5 December 2024.
| Date | 9 Dec 2024 |
| Time | 13:30:29 |
| Category | AGMs and other meetings |
| ID | 3752P |
9 December 2024
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Extraordinary General Meeting
Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Extraordinary General Meeting ("GM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
|
Ordinary Resolutions |
Votes for |
% of votes cast for |
Votes Against |
% of votes cast against |
Total votes cast |
Total votes cast as % of ISC (1) |
Votes with-held (2) |
|
1. To grant the Directors with authority to subdivide and reclassify the existing ordinary shares. |
518,007,554 |
95.39 |
25,041,580 |
4.61 |
543,049,134 |
38.74% |
1,494,053 |
|
2. To grant the Directors with authority to consolidate the New Ordinary Shares. |
518,772,622 |
95.41 |
24,976,512 |
4.59 |
543,749,134 |
38.79% |
794,053 |
|
3. To grant the Directors authority to allot and issue shares and grant rights to subscribe for shares in the Company for the purposes of Section 551 of the Act. |
500,896,092 |
92.24 |
42,153,042 |
7.76 |
543,049,134 |
38.74% |
1,494,053 |
|
Special Resolutions |
Votes for |
% of votes cast for |
Votes against |
% of votes cast against |
Total votes cast |
Total votes cast as % of ISC (1) |
Votes with-held (2) |
|
4. To approve the adoption of the New Articles. |
514,762,980 |
94.80 |
28,213,641 |
5.20 |
542,976,621 |
38.73% |
1,566,566 |
|
5. To dis-apply the statutory rights of pre-emption in respect of the allotment of equity securities for cash under Section 561(1) of the Act. |
493,949,091 |
92.78 |
38,427,061 |
7.22 |
532,376,152 |
37.98% |
12,167,035 |
(1) The Company's issued share capital ("ISC") on 5 December 2024, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,401,815,988 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.
A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
|
|
Peterhouse Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.